|Bid||64.15 x 1000|
|Ask||64.20 x 1800|
|Day's Range||63.60 - 66.74|
|52 Week Range||42.48 - 68.34|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||18.54|
|Earnings Date||Feb 05, 2020|
|Forward Dividend & Yield||1.80 (2.69%)|
|Ex-Dividend Date||Jan 01, 2020|
|1y Target Est||71.90|
Dividend paying stocks like Bristol-Myers Squibb Company (NYSE:BMY) tend to be popular with investors, and for good...
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
Johnson & Johnson (JNJ) receives the European Commission's (EC) nod to the line extension of Stelara to treat six to 11-year-old pediatric patients with moderate-to-severe plaque psoriasis.
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Many other members of Big Pharma spent more on dividends and stock buybacks, a strategy some view as shortsighted Continue reading...
U.S. antitrust officials have begun asking companies about communications with their biggest shareholders as part of merger investigations.
(AMGN) could have a strong year as the turbulence of 2019 fades into the rearview, according to a Wednesday afternoon note by Citi analyst Mohit Bansal. Bansal, who rates the stock a Buy, increased his price target to $275 per share from $245. “We think in 2020 the company could do more than just catching up with the Nasdaq Biotechnology Index as the setup looks even better this time versus 2019,” he wrote.
Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to make breaking announcements, went by without much fanfare ...
With politicians on both sides of the aisle calling for drug price controls, and a number of the Democratic candidates calling for "Medicare for all," it has been a challenging environment for a host of medical sectors, suggests income expert Chuck Carlson, editor of DRIP Investor.
Zacks.com featured highlights include: Genesco, GreenTree Hospitality, Bristol-Myers Squibb, Barclays PLC and Valero Energy